Table 1 Immune checkpoints expression in liver cancers
Cancer type | Number | TNM Stage (I + II / III + IV) | Tumor differentiation (I + II / III + IV) | Tumor size (cm) | Immune checkpoints | Cellular expression | Year | Reference |
|---|---|---|---|---|---|---|---|---|
Human HCC | 217 (tumor samples) | Operable, resected | 101 (46%)/ 116 (53%) | 7.26 (1.0–2.5) | PD-L1/PD-1 | neoplastic and inflammatory cells | 2016 | [24] |
Human HCC | 176 | 97/52 | 112/64 | 5.3 (PD-L1 low)/4.9 (PD-L1 high) | PD-L1 | CD68+ macrophages | 2016 | [27] |
Human HCC | 90 | Operable, resected | 73/17 | 4.2 (1.3–15) | PD-L1 | peritumoral hepatocytes | 2017 | [25] |
Human HCC | 294 | 59/87 | 140/6 | 110(<5) /36(≥5) | PD-L1/PD-1 and CTLA-4 | tumor infiltrating | 2017 | [26] |
Human HCC | 69 | 35/34 | 50/19 | 7/21(Tim-3 low)/17/24 (Tim-3 high) | Tim-3 | CD14+ monocytes | 2015 | [28] |
Human HCC | 171 | 100/71 | NR | 98/73 | PD-1 and Tim-3 | neoplastic and inflammatory cells | 2016 | [29] |
Human ICC | 31 | 9/22 | 13/18 | 20 (<5) / 11 (>5) | PD-L1 and PD-1 | neoplastic and inflammatory cells | 2009 | [38] |
Human ICC | 27 | 16/11 | 19/8 | NR | PD-L1 | ICC cells | 2016 | [36] |